[1] EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol,2019,70: 1222-1261.
[2] Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in Mainland China. Gastroenterology,2019,156:2230-2241.
[3] Kullak-Ublick GA, Andrade RJ, Merz M, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut,2017,66: 1154-1164.
[4] Kaliyaperumal K, Grove JI, Delahay RM, et al.Pharma-cogenomics of drug-induced liver injury (DILI): Molecular biology to clinical applications. J Hepatol, 2018,69: 948-957.
[5] Li C, Rao T, Chen X, et al. HLA-B*35:01 allele is a potential biomarker for predicting polygonum multiflorum-induced liver injury in humans. Hepatology,2019,70: 346-357.
[6] Lei X, Chen J, Ren J, et al. Liver damage associated with polygonum multiflorum thunb.: a systematic review of case reports and case series. Evid Based Complement Alternat Med,2015,2015: 459749. |
